Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Non-cash Items (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Non-cash Items for 10 consecutive years, with $153000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non-cash Items fell 95.47% to $153000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $153000.0, a 95.47% decrease, with the full-year FY2024 number at $1.6 million, down 14.73% from a year prior.
  • Non-cash Items was $153000.0 for Q3 2025 at Rein Therapeutics, down from $2.0 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $5.3 million in Q3 2022 to a low of $26000.0 in Q1 2022.
  • A 5-year average of $1.8 million and a median of $1.6 million in 2024 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: tumbled 97.97% in 2022, then skyrocketed 1126.12% in 2023.
  • Rein Therapeutics' Non-cash Items stood at $2.9 million in 2021, then plummeted by 90.19% to $288821.0 in 2022, then skyrocketed by 905.81% to $2.9 million in 2023, then crashed by 44.75% to $1.6 million in 2024, then plummeted by 90.47% to $153000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Non-cash Items are $153000.0 (Q3 2025), $2.0 million (Q2 2025), and $2.0 million (Q1 2025).